InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,071.63
(
0.02%
)
US TECH 100
16,868.40
(
-0.79%
)
Dow Jones
38,460.92
(
-0.11%
)
Brent Oil
87.18
(
-0.05%
)
Bitcoin
64,358.60
(
0.12%
)
Post# of 438
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DanWebzster

Send PM Follow Ignore
Followers 10
Posts 1060
Boards Moderated 2
Alias Born 09/04/2000

DanWebzster

Member Level

Re: DanWebzster post# 208

Wednesday, 06/20/2018 11:32:02 AM

Wednesday, June 20, 2018 11:32:02 AM

Post# of 438
KDMN 's recent secondary offering extends cash runway into Q3/19

KDMN has 3 initiatives that are working well for it:

1) Positive Ph2 data in idiopathic pulmonary fibrosis in patients previously treated with pirfenidone and/or nintedinib bodes well for ROCK inhibitor platform in other fibrotic diseases.

2) Lead candidate is likely to establish a niche in treating cGVHD over ibrutinib.

3) 13% ownership in recent gene therapy IPO, MGTX
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up